A primate model system was used to identify Chlamydia trachomatis antigens uniquely recognized in the context of infection. Serum antibody titres were measured in cynomolgus monkeys challenged urethrally with C. trachomatis serovar L2 elementary bodies (EBs). High-titre sera from these primates were used, in parallel with antisera against killed C. trachomatis EBs, to differentially screen an expression library of C. trachomatis serovar U DNA.
INTRODUCTION
Chlamydiae are obligate intracellular bacterial pathogens with a unique biphasic life cycle. They appear as two distinct cellular types, a small (0-3 pm) dense form with a rigid cell wall, termed the elementary body (EB), and a larger metabolically active but noninfectious
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.~ ~~ t ra ch o ma t is a n d Ch 1 a m y d ia p n eu m o n iae . Sex u a 1 1 y transmitted C. trachomatis leads t o a spectrum of serious clinical conditions a n d conjunctival infection can cause trachoma, the leading cause of infectious blindness worldwide (Hillis et al., 1997; Thylefors et al., 199.5) . Additionally there is both laboratory a n d epidemiological evidence that chlamydia] infection can facilitate the spread of HIV (Wasserheit, 1994) . C. pnerimoniae is :I recently recognized species t h a t causes acute respiratory diseases a n d is currently of interest because of its epidemiological association with asthma ( H a h n et al., 1991) a n d cardiovascular disease (Danesh et a/., 1997) .
T h e r e is widespread interest in the identification of cii n d id 1 1 t e A 11 t ige n s f o r p rot ec t i o n aga i ns t c h 1 a m y d i a 1 disease, but the demonstration of any single protective antigen remains elusive. Recent reports have described protection mediated by a DNA vaccine using the o m p l gene, suggesting its gene product, the major outermembrane protein (MOMP), may be a protective antigen. These studies are confounded by the inability of purified MOMP t o protect in any subunit vaccine trial, nnd by the inability of ompl-mediated DNA vaccines t o w o r k a t a11 mucosal sites ( Z h a n g et al ., 1997) . T h e r e is also very recent evidence suggesting EB antigens presented t o cytokine-stimulated dendritic cells can be used t o confer protection in a murine model system (Su et al., 1998) .
While a prior infection with C. trachomatis will provide specific, short-term protection against a subsequent challenge, many chlamydial diseases are exacerbated by a n ovcr:ig:gressive immune response against EB structura! components, possibly including either o r both of t w o genus-common proteins (Morrison et a/., 1992; Bachmaier et a/., 1999) . T h e distinction between the immune response in infected animals versus that seen in animals immunized with killed chlamydiae has been ex:i.niined previously in a guinea pig model of chlamydial conjunctivitis, caused by Chlamydia psittaci strain Guinea Pig Inclusion Conjunctivitis (GPIC) (Rockey & Rosquist, 1994) . T h i s approach led t o the identification of chlamydia1 proteins (IncA, B a n d C) localized t o the inclusion membrane o f both C. psittaci-a n d C. trachomatis-infected cells (Bannantine et al., 1998a, b ; Rockey et al., 199.5) . In the present report, w e have explored the use o f a primate infection model of chlamydia] genital infection for the purpose of uncovering novel C. trachomatis antigens recognized uniquely in the context of infection. T w o previously unidentified antigenic proteins were identified, each under-represented in EBs a n d localized t o developmental forms a t the margins of the inclusion. H u m a n s w h o have acquired a sexually transmitted chlamydia] infection also recognize these proteins.
METHODS
Animals, infections and antisera. For this study, two male cynomolgus monkeys (Macaca fasicularis) weighing 5.4 and 5.2 kg were used. These animals, designated no. 102 and no.
2078
-894, were housed independently in the animal facilities at Rocky Mountain Laboratories. All experiments and immunizations were approved by an Institutional Animal Care and Use Committee as required by the Animal Use Welfare act. Monkeys anaesthetized with ketamine-HC1 were infected urethrally with a sterile calcium alginate swab saturated with a solution of lo9 C. trachomatis LGV-434 serotype L2 EBs ml-'. Animals were infected three times over the course of 18 months and allowed to recover between infections. Clinical signs were monitored weekly. Sera were collected every 2 weeks and analysed by immunoblotting (Rockey et al., 1995) and ELISA (Su et al., 1990) for reactivity with chlamydia] antigens. High-titre serum from animal no. 894 collected 8 weeks after the secondary challenge (convalescent sera) was used to screen the genomic library.
Because of the expense associated with generating control antisera in primates, guinea pigs were used to produce antisera against C. trachomatis L2 EBs inactivated with 10 '% formalin-PBS. Fixed EBs ( 109 EBs ml-') were emulsified in Ribi trivalent adjuvant (Sigma) and injected twice over the course of 2 months using a protocol provided by the manufacturer. The resulting sera (a-EB antisera) were checked for reactivity to C. trachomatis EBs by immunoblotting and used to probe the C. trachomatis expression library. Antisera against purified recombinant proteins were produced in New Zealand White rabbits and BALB/c mice using antigens emulsified in Ribi adjuvant. Anti-chlamydia1 Hsp6O mAb A57B9 was collected from hybridoma culture supernatants as described by Yuan et a/. (1992) .
Human sera that demonstrated high-titre antibody to C. trachomatis or C. pneumoniae by microimmunofluorescence assay were selected from stored serum specimens at the University of Washington. Both anti-C. trachomatis and control antisera were taken from patients in a clinical setting and analysed for reactivity by microimmunofluorescence against C. trachomatis and C. pneumoniae strain TWAR. The control antisera showed no detectable reactivity when using this assay.
Bacteria, bacteriophage and Ii brary construction. C. trachomatis LGV-434, serotype L2, was cultivated in HeLa 229 cells and purified using density centrifugation as previously described by Caldwell et al. (1981) and Hackstadt et al. (1992) . Escherichia coli DHSn (Bethesda Research Laboratories) was used as the host strain for transformations with recombinant DNA. E. coli XL-1 Blue MRF' (Stratagene) was used as the host strain for infection with lambda ZAPII bacteriophage vector. A C. trachomatis genomic library was constructed with the lambda ZAPII vector as previously described for C. psittaci (Bannantine et al., 1998a) . Library plaques were plated, transferred to nitrocellulose filters (Schleicher & Schuell) in duplicate and probed with monkey convalescent antiserum and guinea pig a-EB sera. Plaques that were recognized by the convalescent antiserum, but not the a-EB sera, were selected for further study. Coinfection of E. coli SOLR (Stratagene) with purified candidate lambda clones and with ExAssist helper bacteriophage (Stratagene) resulted in SOLR clones harbouring pBluescript containing C. trachomatis inserts of interest.
Nucleotide sequencing and sequence analysis. Automated sequencing was performed with the Taq DyeDeoxy Terminator Cycle Sequencing kit (Perkin Elmer/Applied Biosystems Division) on an ABI377 sequencer (Oregon State University Central Services). Sequence assembly was performed using AssemblyLIGN software and sequence analysis was performed with MacVector software (Oxford Molecular). Deduced amino acid sequences were compared with genomic databases using the BLAST program available from the National Center for Biotechnology Information on the World Wide Web.
Production of maltose-binding protein (MBP) fusion
proteins. MBP fusions of TroA, TroB and p242 were constructed using the pMAL-c2 vector (New England Biolabs). The reading frame of each gene was amplified using Pwo DNA polymerase (Boehringer Mannheim) and serovar L2 genomic DNA as the template. The upstream and downstream oligonucleotides for these amplifications are as 3' and 5'-GCGCGGATCCTATTCAAGAACAGTCCCTC-CCA-3' ; troB, 5'-ATGTCTGTGATAACTATTTTAGCAC-3' and 5'-GCGCGGATCCTCAGCATCTAGCACGATCC-CT-3' and 5'-GCGCGGATCCTAGCTTCGCATGTTAAT-TATTT-3'. The vector was digested sequentially with XmnI and BamHI, and the amplification product was digested with BamHI. Ligation of these products resulted in in-frame fusions between the vector-encoded malE gene and the chlamydial genes of interest. The resulting fusion proteins were overproduced in E. coli DHSa and subsequently purified by affinity chromatography using an amylose resin (New England Biolabs). The purified MBP fusion proteins were used as antigen for the production G f monospecific antibody in mice and/or rabbits by the method of Rockey et al. (1995) . / o SDS ; 50 mM Tris, pH 6.8 ; 1 ' / o 2-mercaptoethanol ; 10 '/o glycerol). Lysates were pooled, boiled for 5 min and stored at -20 "C.
Electrophoresis and immunoblotting. PAGE and immunoblotting were conducted as described previously (Rockey & Rosquist, 1994; Rockey et al., 1995) . Rabbit primary antibody was detected with [35S]Protein A (4600 Bq m1-l; Amersham) diluted 1:500 in PBS/O.l% Tween 20/2% BSA. Mouse antibodies were detected with peroxidase-conjugated secondary antibodies diluted 1 : 5000 and chemiluminescence (ECL reagent ; Amersham). Slot-blot analyses of monkey test bleeds and human sera were performed using a Mini-Protean I1 Multiscreen apparatus (Bio-Rad) as described by Rockey et al. (1996) . Autoradiographs were subsequently scanned into digital images and processed using Photoshop (Adobe Systems) and Canvas (Deneba Software) graphics programs.
lmmunofluorescence studies. Chlamydiae grown in HeLa cells on sterile glass coverslips were methanol-fixed 20-35 h PI. These fixed coverslips were immunostained using mouse anti-TroA, mouse anti-p242 and/or rabbit anti-IncA diluted in PBS containing 3% (w/v) BSA (PBS-BSA), followed by FITC-conjugated goat anti-mouse IgG and rhodamineconjugated goat anti-rabbit IgG diluted in PBS-BSA. Immunostaining of the fixed coverslips was performed according to the method of Rockey & Rosquist (1994) and visualized with the ~6 3 objective of a Zeiss microscope equipped with an epifluorescence condenser and MC 63 C photomicrographic camera.
follows : troA, 5'-ATGAATCGCATGATTTGTGATTGCG-TTG-3' ; D242, 5'-ATGAAAAAGTTCTTATTACTTAG-
RESULTS

Characterization of primate response to infection
T h e C. trachomatis-infected cynomolgus monkeys displayed markedly enlarged inguinal lymph nodes beginning 2 weeks post-primary challenge and these remained enlarged until 10 weeks post-challenge. Serum antibody titres against C. trachomatis increased in both animals during the 12 weeks following the primary challenge (Fig. 1) . A secondary challenge was administered 14 weeks post-primary. Inguinal lymph nodes were again enlarged in both animals following secondary infection. Serum antibody titres from animal no. 894 remained high following secondary challenge while anti-chlamydia1 titres dropped in animal no. 102. A tertiary challenge was administered to each monkey but this had n o effect o n antibody levels in either animal -titres of no. 102 remained low while no. 894 remained high throughout the course of the challenges. There was n o urethral discharge, fever, o r weight loss in either animal following any of the three chlamydial challenges.
Results obtained by immunoblotting with the primate antisera correlated well with that observed by ELISA (not shown). These blots were also used t o identify unique antigens that might be recognized only in the context of infection. T w o proteins appeared to be more abundant in the blots of infected cells -one of 28 kDa and one above 90 kDa.
Identification of antigens recognized by convalescent antisera
Because of the higher and more consistent antibody titre, serum from animal no. 894 collected 8 weeks after the secondary challenge was used to screen a bacteriophage expression library of C. trachomatis DNA. Four plaques from the C. trachomatis library were recognized by serum from animal no. 894, but not by a-EB sera. SDS-PAGE and immunoblot analysis of E. cofi harbouring the chlamydial inserts showed that each produced one o r more proteins that were recognized by serum from animal no. 894 but not by four independent guinea pig a-EB sera (Fig. 2) . E. coli/pCtl produced a 28 kDa antigenic protein, E. colilpCt2 and E. cofilpCt3 produced a 20 kDa antigenic protein and E. cofilpCt4 produced multiple proteins a t 32-34 kDa. Blotting was essentially identical when high-titre serum from infected animal no. 102 (collected 12 weeks post-primary infection) was used, indicating that these proteins were immunogenic following infection of t w o different monkeys.
Sequence analysis of immunoreactive genomic clones
Sequence analysis of recombinants revealed that three of four clones (pCt1, pCt2 and pCt3) were overlapping and contained only one common ORF. This common O R F is virtually identical to O R F D242 (contig 3.7) in the C. trachomatis serovar D genome sequence (Stephens et af., 1998) and it encodes a protein product lacking significant similarity to any known proteins in the sequence databases. Because of this lack of known function we refer to the product from O R F D242 as p242. This protein was encoded in its entirety within pCt2 and pCt3. T h e larger antigenic protein observed in E . coli/pCtl (Fig. 23) (Stephens et al., 1998) show that these proteins are 100% conserved between the two C. trachomatis serovars.
Production of fusion proteins and immunoblot analysis
Because both TroA and TroB were encoded in their entirety on pCt4, it was not clear which protein was recognized by the convalescent antisera. To address this and other questions, MBP fusions of TroA, TroB and p242 were constructed and expressed in E . coli. Lysates containing each fusion protein were prepared and analysed by immunoblotting with selected antibodies (Fig. 3) . Each purified protein was detected with antibody that recognizes the MBP portion of the fusion protein (Fig. 3a) , and none were recognized by the akilled EB sera (Fig. 3c) , consistent with their initial characterization as infection-specific antigens. Immunoblots of uninduced and IPTG-induced E . coli lysates of each MBP fusion were then probed with primate convalescent sera (Fig. 3b) . This experiment showed that the convalescent sera from both primates recognized TroA and p242, but not TroB. showed no reactivity with TroA and one patient showed reactivity with p242. The M B P portion of these fusions was not detected or was weakly detected by the patient sera. Lanes: 1 and 2, negative control sera; 3-13, sera from 11 patients that have been infected with C. trachornatis; 14-15, sera from t w o patients that have been infected with C. pneumoniae.
-~
The TroA and p242 MBP fusions were then used as antigens in immunoblot analysis of sera from patients with high-titre anti-C. trachomatis serum antibodies (Fig. 4) . These patients had histories of infection with a variety of the oculogenital chlamydia1 serovars. These sera were compared to sera from patients with evidence of C. pneumoniae infection (Fig. 4, lanes 14 and 15) , and to sera from patients with no evidence of serum antibodies against Chlamydia (Fig. 4, lanes 1 and 2) . TroA was recognized by sera from 8 of 11 C. trachomatis-infected patients, and 10 of 11 C. trachomatis-infected patients showed specific reactivity with p242 (Fig. 4, lanes 3-13) . Serum from one C.
pneumoniae-infected patient recognized p242, but that same serum showed relatively high background against MBP alone. Neither of the C. pneumoniae patient sera detected TroA.
The three purified MBP fusions were also used to immunize mice and/or rabbits for the production of monospecific antisera. These sera were used to probe immunoblots of mock-infected HeLa cells, C. trachomatis-infected HeLa cells and purified EBs (Fig.   5 ) . Similar amounts of C. trachomatis antigen are present in the infected cells and purified EB lysates, as shown in the immunoblot probed with anti-Hsp60 mAb (Fig. 5a ). However, both TroA and p242 are present in higher amounts in the infected cells as compared to the purified EBs (Fig. 5b, c) . 
I m m u nof I uorescence microscopy
T h e location of TroA and the p242 gene product within infected HeLa cells was determined by indirect immunofluorescence microscopy (Fig. 6) . A virtually identical staining pattern was observed for TroA ( Fig. 6a) and p242 (Fig. 6c) . Inclusion membrane staining with anti-C. trachomatis IncA (Bannantine et al., 1998b) is also shown for comparative illustration purposes (Fig. 6b, d ).
Both TroA and p242 were localized to the chlamydial developmental forms adjacent to the inclusion membrane within the infected cell and rippeared to localize to the cell wall of chlamydial developmental forms.
DISCUSSION
Previous studies have suggested that prior chlamydial infection of animals o r humans protects against a subsequent homologous challenge (Morrison et al., 1992) . While antigens presented in the context of infection appear to elicit a protective immune response,
immunization with purified, killed Chlamydia may lead to more severe sequelae following subsequent infection. Therefore, a driving force behind the current studies was to identify antigenic proteins that are recognized uniquely during C. trachomatis infection, as they may be uniquely associated with a protective immune response.
A urethral challenge of primates with C . trachomatis serovar L2 was used as a challenge system representative of primary human infection with a lymphogranuloma serovar. This type of challenge was used, as opposed to challenge with a classic oculogenital serovar, because of the ability of LGV infection to stimulate higher serum antibody titres (Perine & Stamm, 1999) . Clinical disease was monitored following infection, but the only apparent signs were transiently enlarged inguinal lymph nodes in each infected animal. Such swelling is a hallmark of C. trachomatis LGV infections in humans.
In untreated cases the swelling and subsequent symptomology can be severe, but n o such problems were observed in the experimentally infected primates. Antibody titres in these animals rapidly increased following primary challenge. One animal experienced Four bacteriophage clones showed exclusive reactivity with convalescent sera. Of these, three produced p242.
Investigation of the genome databases has revealed no clues as to the function of this protein, although it bears some similarity to OmpH of Yersinia pseudotu6ercufosis. Upstream of ORF D242 is yaeT, which encodes a protein with strong similarity to several prokaryotic outer-membrane proteins, including a putative protective surface antigen in Haernophifus influenzue (Thomas et af., 1990) . Downstream of ORF D242 is f p x D , a gene found in many bacterial species that encodes a protein involved in lipid A biosynthesis.
Several bacterial genomes encode both f p x D and yaeT but these genes have not been shown to be linked in any organisms except the chlamydiae (Tomb et af., 1997; Fleischmann et af., 1995; Cole et af., 1998) .
The last clone encodes two complete ORFs and one partial ORF, each of which shares similarity with genes in the tro operon of T . paffidurn. troA is expressed as part of an operon in T . paffidurn and is predicted to encode an ABC transport system; however, no definite function has been assigned. This T . paffidurn operon consists of six genes, troABCDR and pgrn (Hardham et al., 1997) . The corresponding operon in C . trachornatis contains only troABCD (Stephens et af., 1998 ). An immunological parallel exists between the immune responses to TroA from Treponerna and Chlamydia; T . paffidurn TroA is also antigenic in experimentally infected animals (rabbits) and syphilitic patients (Blanco et af., 1995; Hardham et af., 1997) . Additionally, a potential role is proposed for TroA (also called TROMP1) in acquired immunity against syphilis. Freeze-fracture electron microscopy has demonstrated the ability of serum from immune syphilitic rabbits to aggregate TROMPS (Blanco et af., 1990) . Serum from T .
paffidurn-infected rabbits with varying degrees of challenge immunity have shown that TROMP aggregation correlates directly with the development of immunity (Lewinski et af., 1995) .
The location and function of TroA in T . paffidurn are controversial. Some studies indicate that TroA functions as an integral outer-membrane porin (Blanco et af., 1995 (Blanco et af., , 1996 , while other studies show that the protein is not exported, but rather is tethered to the cytoplasmic membrane by an uncleaved signal sequence (Akins et af., 1997) . C . trachornatis TroA also possesses a predicted uncleavable signal sequence, and we have shown this protein to be associated with the cell wall of intracellular developmental forms (Fig. 6a) . Fluorescence microscopy also indicated that p242 is similarly localized (Fig. 6c) , and analysis of its amino acid sequence demonstrates a classical signal peptide (not shown). Both TroA and p242 are therefore localized to the chlamydial envelope, and each is relatively under-represented in EBs (Fig. 5 ) . Further research will address kinetics of protein accumulation and decay during the chlamydial developmental cycle.
Convalescent sera from animals experimentally infected with chlamydiae have been used successfully in this study and others to identify a collection of antigenic chlamydial proteins recognized predominantly in the context of infection. In each case, identified antigens are relatively under-represented in EBs. The present study uses a primate model system of chlamydial genital infection to identify TroA and p242, proteins present in infected cells but under-represented in EBs. Similar experimentation in a guinea pig model of chlamydial conjunctivitis led to the identification of proteins uniquely present in the chlamydial inclusion membrane within infected cells (Bannantine et al., 1998a, b; Rockey et al., 1995) . Each of these proteins, IncA, IncB and IncC, was also found in RBs but none was detected in EBs.
While each system has been useful in identifying novel antigenic proteins, the approach is somewhat limited in cases where proteins do not elicit strong antibody responses. This was particularly evident with the guinea pig system, where the inclusion membrane protein IncC was identified because incC was adjacent to and cotranscribed with incB (Bannantine et af., 1998a) . IncC would not have been identified as a protein in the inclusion membrane if incC had not been adjacent to incB in the genome. An example of this from the current study is TroB, encoded by the second gene in the C. trachomatis tro operon. TroB was not recognized by the convalescent sera and was not directly identified in this system. While this is problematic for uncovering unique proteins such as IncC and TroB, it is seriously limiting for the identification of potential infection-specific antigens that do not stimulate strong antibody production but may be critically important in host-cellmediated immune responses.
Optimally we would have used monkeys to produce the antisera against killed EBs as the control in these experiments. Because of resource and animal limitations, we chose instead to produce the anti-EB antisera in guinea pigs. The guinea pig sera were carefully tested, but the difference in host species introduces additional variables that cannot be controlled for. For example, guinea pigs immunized parenterally with killed EBs may respond differently to similarly immunized monkeys. Such inherent problems with these controls may lead to improper assignment of antigens as infection-specific. In the present experiments, however, our conclusion that TroA and p242 are not present in EBs is also supported by immunoblot analysis with monospecific antisera, which showed each protein to be under-represented in EBs (Fig. 5 ) . Therefore the guinea pig antisera were appropriate as a control for identification of antigens present uniquely in the context of infection.
Little information exists about the ability of individual C. trachomatis proteins to induce protective immunity. While the importance of TroA and p242 in immunity against chlamydial disease is currently unknown, it is apparent that each of these novel proteins is antigenic in the context of infection of both humans and monkeys. We are currently using a vaccinia-based system to investigate the protective ability of these and other infection-specific proteins, and we are hopeful that such investigations can identify candidate proteins for use in subunit vaccines against chlamydial infection, W e gratefully acknowledge Richard Stephens a n d Claudia
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Michael I'arnell provided valuable assistance with the infection a n d monitoring of the monkeys a n d the production of primate convalescent sera. Finally, w e thank Dennis H r u b y a n d Tiffany Bolmann for their contributions t o this work. 
